Bill Crossman is an unlikely candidate to run a pharmaceutical firm.

The 71-year-old Connecticut businessman had spent decades growing a diverse collection of companies making everything from elevators to eco-friendly products. He had never run a drug company — and had little to no experience in the industry.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hopefully the claims he makes turn out to be true in humans. If it does reach market physicians would likely still provide abusive drugs – look at the slow up take of abuse deterrent opioids (just get the non deterrent generic instead).

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy